拉米夫定联合苦参素治疗慢性乙型肝炎68例临床观察

Clinical study of lamivudine combined with kurorinone in the treatment of chronic hepatitis B.

目的 探讨拉米夫定(LAM)联合苦参素治疗慢性乙型肝炎(CHB)患者的临床疗效。方法 将慢性乙型肝炎患者13 4例随机分为治疗组(68例)与对照组(66例)。治疗组给予LAM联合苦参素治疗;对照组单用LAM。疗程6个月,随访6个月。观察治疗前后的血生化,HBeAg ,HBVDNA等指标的变化情况。结果 疗程结束后和停药6个月后,治疗组患者血清HBeAg、HBVDNA等指标显著下降,与对照组比较差异有显著性(P <0 .0 5或P <0 .0 1)。结论 LAM联合苦参素治疗CHB疗效优于LAM单一用药。

Objective To study the efficacy of lamivudine(LAM)combined with kurorinone in the treatment of chronic hepatitis B.Methods 134 patients with chronic hepatitis B(CHB)were randomly divided into two groups.Patients of the treatment group were given lamivudine 0.1,p.o,q.d,and kurorinone 0.2,p.o,tid,while those of the control group were given lamivudine alone.The course of treatment in both groups lasted for 6 months.Changes in liver function,serum levels of HBeAg,HBV DNA before and after treatment were kept under observation.Results After being treated for 6 months and 6 months after its withdrawal,serum levels of HBeAg,HBV DNA in the treatment group showed significant lower than in the control group(P<0.05 or P<0.01).Conclusion LAM combined with kurorinone is more effective than lamivudine alone for treating patients with chronic hepatitis B.